Subtitle
Evaluating the safety and efficacy of proton radiotherapy for intracranial pediatric ependymomas: A single-arm meta-analysis.
Subtitle
Evaluating the safety and efficacy of proton radiotherapy for intracranial pediatric ependymomas: A single-arm meta-analysis.
Proto therapy Time
December 2024
Executive summary
Based on data from 10 primary studies comprising 908 patients with ependymoma, this systematic review reported 5-year local control of 79%, event-free survival of 65%, and overall survival of 83%. Neurological, dermatological and brainstem complications were 17%, 20% and 3%. The authors concluded that proton radiotherapy appeared safe and effective based on current data.
Top cancer treatments
Related contents
Proton Therapy Publication

November 2024
Proton beam therapy for craniopharyngioma: a systematic review and meta-analysis
en
Proton Therapy Publication

November 2024
Systematic review and meta-analysis of photon radiotherapy versus proton beam therapy for pediatric intracranial ependymoma: TRP-ependymoma 2024
en
Proton Therapy Publication

December 2024
Osteoradionecrosis in Pediatric Patients Treated with Proton Therapy for Head and Neck Malignancies.
en
Webinar

18 October 2024
Empowering Cancer Care with Proton Therapy
Rakesh
Jalali
Srinivas
Chilukuri
Daniela
Alterio
en
Proton Therapy Publication

September 2024
Outcomes of proton therapy to infradiaphragmatic sites in pediatric patients with Hodgkin lymphoma.
en
Proton Therapy Publication

September 2024
Long-term outcomes following proton therapy for pediatric spinal low-grade glioma.
en
Proton Therapy Publication

June 2024
Late-onset lymphopenia during radiation is associated with an increased risk of tumor recurrence in newly diagnosed pediatric medulloblastoma.
en
Proton Therapy Publication

May 2024
Proton Therapy in Non-Rhabdomyosarcoma Soft Tissue Sarcomas of Children and Adolescents.
en
Proton Therapy Publication

May 2024
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma.
en